Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;24(7):809-817.
doi: 10.1007/s11912-022-01266-4. Epub 2022 Mar 19.

Bystander effect of antibody-drug conjugates: fact or fiction?

Federica Giugliano  1   2 , Chiara Corti  1   2 , Paolo Tarantino  3   4   5 , Flavia Michelini  6   7 , Giuseppe Curigliano  1   2
Affiliations
Review

Bystander effect of antibody-drug conjugates: fact or fiction?

Federica Giugliano et al. Curr Oncol Rep. 2022 Jul.

Abstract

Purpose of review: Summarizing the current preclinical and clinical evidence about bystander effect of antibody-drug conjugates (ADCs) in solid tumors.

Recent findings: One of the main challenges of treating solid tumors with ADCs is the heterogeneous expression of the target antigen (Ag), which however may be overcome by the so-called bystander killing effect. This unique, but still debated, feature of certain ADCs is represented by the unintentional payload diffusion from Ag-positive tumor cells to adjacent Ag-negative tumor cells. Some pharmacological characteristics, such as a hydrophobic payload or a cleavable linker, seem to play a major role in this effect. Abundant preclinical evidence of the bystander effect has emerged, and the clinical activity of ADCs in tumors with a heterogeneous Ag expression suggests the relevance of this feature. Additional studies are required to investigate if the bystander effect is necessary for achieving a solid activity with ADCs.

Keywords: Antibody–drug conjugates; Bystander effect; Sacituzumab govitecan; Trastuzumab deruxtecan; Trastuzumab emtansine.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. •• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol [Internet]. 2021 Jun 8;18(6):327–44. Available from: http://www.nature.com/articles/s41571-021-00470-8 . This is a comprhensive review on the topic of ADCs.
    1. Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer [Internet]. 2008;8(6):473–80. Available from: http://www.nature.com/articles/nrc2394 .
    1. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs [Internet]. 2016 May 18;8(4):659–71. Available from: http://www.tandfonline.com/doi/full/10.1080/19420862.2016.1156829.
    1. Kovtun Y V., Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res [Internet]. 2006 Mar 15;66(6):3214–21. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-05-3973.
    1. Kovtun Y V., Goldmacher VS. Cell killing by antibody–drug conjugates. Cancer Lett [Internet]. 2007 Oct;255(2):232–40. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304383507001991 .

MeSH terms

LinkOut - more resources